PKF South Africa https://cerbalancetafrica.com.gh/ MDS Lancet Laboratories Ltd won Customers’ Choice Medical Diagnostic Company Of The Year 2021

The 2021 National Customers’ Choice Awards recognizes the brand that consistently delivers quality products or services to its customers and honors companies and individuals who go that extra mile for their customers .

The 2021 National Customers’ Choice Awards recognizes the brand that consistently delivers quality products or services to its customers and honors companies and individuals who go that extra mile for their customers .

The awards event was organized by KN Unique Communications, one of the leading corporate events management companies in Ghana, with brand engagement across the world on the 15th of October, 2021.

A total of 30 companies and 4 individuals were honoured at the 2021 National Customers’ Choice Awards Ghana which seeks to recognize outstanding businesses through the lens of the customer.

Oheneba Kwabena Kena, the Event Director noted that “It is a true reflection of the marketplace as it represents the views of consumers and buyers across the nation. This award recognizes the brand that consistently delivers a high level of service to its customers. Each year, the KN Unique Communications will recognize the best companies for their earnest efforts in business excellence and keeping the customer’s best interests in mind.”

He stated that “The National Customers’ Choice Awards Ghana (NCCAG) is an event organized to solely recognize business excellence by conducting a comprehensive and objective accurate independent market research survey, to determine brand reputation, customer satisfaction and business excellence for the quality of their service, value, professionalism and integrity.”

MDS Lancet Laboratories Ltd won Customers’ Choice Medical Diagnostic Company Of The Year.

]]>
10/19/2021 12:00:00 PM https://cerbalancetafrica.com.gh/news/press-releases/customers-choice-medical-diagnostic-company-of-the-year-2021/
Cerba Lancet Africa signs strategic partnership with international Clinical Laboratories in Ethiopia

Johannesburg (South Africa) and Addis-Ababa (Ethiopia), 29th September 2022 - Cerba Lancet Africa, a benchmark in the field of medical diagnosis in Africa, today announced it has signed a strategic partnership with International Clinical Laboratories (ICL) Ethiopia, the leading private clinical pathology laboratory in the country serving more than 3 million patients over the past 17 years.

  • The partnership* illustrates Cerba HealthCare’s strategy to support long term health response locally and increase patient access to a broader range of laboratory testing across the continent
  • International Clinical Laboratories (ICL) will leverage the world-class expertise range of Cerba HealthCare and its existing pan-African network Cerba Lancet Africa to sustainably meet the diagnostic tool expectations of patients, physicians and hospitals nationwide.

Johannesburg (South Africa) and Addis-Ababa (Ethiopia), 29th September 2022 - Cerba Lancet Africa, a benchmark in the field of medical diagnosis in Africa, today announced it has signed a strategic partnership with International Clinical Laboratories (ICL) Ethiopia, the leading private clinical pathology laboratory in the country serving more than 3 million patients over the past 17 years.

Cerba Lancet Africa is majority owned by the French group Cerba HealthCare, benefiting from a unique positioning on the whole value chain of medical diagnosis: alongside a worldwide presence through its expertise in clinical pathology for clinical trials, the Group has sound positions in Europe and Africa thanks to its historical activities in routine and specialty clinical pathology. Cerba HealthCare set foot on the African continent in 2019 where it operates today in 15 countries under the Cerba Lancet Africa umbrella, providing access to accurate diagnosis and high-quality care to more almost 3 million people yearly.

In Ethiopia, ICL stands as the reference player in clinical pathology with unparalleled experience and reputation. Its strong presence all over the country allowed the ICL’s team to play a critical role in handling the COVID-19 pandemic, which has exposed vulnerabilities of the numerous health systems across the globe and specifically the African one, together with the need for increased testing and diagnostic services.

Download Press Release

]]>
10/5/2022 12:00:00 PM https://cerbalancetafrica.com.gh/news/press-releases/cerba-lancet-africa-signs-strategic-partnership-with-international-clinical-laboratories-in-ethiopia/
Cerba And Taliaz to leverage Artificial Intelligence and Genetics Expertise to improve patient care management in depression

Saint Ouen l’Aumône (France) and Tel Aviv (Israel), October 20th, 2022 - Cerba, the foremost specialty clinical pathology reference, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, announced today a partnership to provide physicians with an AI-driven precision psychiatry solution that predicts treatment effectiveness in depression.

Saint Ouen l’Aumône (France) and Tel Aviv (Israel), October 20th, 2022 – Cerba, the foremost specialty clinical pathology reference, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, announced today a partnership to provide physicians with an AI-driven precision psychiatry solution that predicts treatment effectiveness in depression. By finding the right treatment from the very first prescription, the test helps physicians make the best therapeutic decision faster for their patients and can accelerate recovery of the 280 million people suffering from depression globally.

Today, 5% of the world’s adult population suffer from depression, one of the most common mental health disorders, according to the World Health Organization. The correct medical prescription of antidepressant compounds has become a critical issue in patient management as a lack of response or remission occurs in 20-30% of patients with a severe depressive episode. In France alone, 1 in 4 people struggle with mental health disorders, and 1 in 5 people suffer from depression.

To face this challenge, Cerba and Taliaz have joined forces to provide clinicians with a new clinical test that predicts the effectiveness of antidepressant treatments: PREDICTIX, developed by Taliaz, harnesses a biological test coupled with artificial intelligence to guide the management of depressed patients by presenting the medication with the best chance of therapeutic success the first time. Designed as a clinical decision support tool, the solution brings AI-driven precision psychiatry to the next level and is expected to improve care for millions of patients globally. It should be available for patients by January 2023 throughout the Cerba HealthCare clinical routine pathology network in France and abroad.

The PREDICTIX test uses AI to analyse multiple streams of patients’ data, including genetic, metabolic, demographic and clinical information. Doctors receive a personalized patient report that predicts and ranks the statistical efficacy, dosage and potential side effects of various antidepressant medications based on each patient’s pharmacogenetic makeup and health record. Clinical research demonstrated a response rate of 72.2 % and real-world data showed 90 % of patients experienced clinical improvement after 8 weeks according to the Clinical Global Impressions (CGI) Scale, a useful tool for clinicians and patients used in clinical practice.

Jérôme Sallette, Chief Scientific Officer at Cerba HealthCare comments: "With the introduction of PREDICTIX, we are entering a new age of precision medicine in psychiatry: empowering physicians to make the best therapeutic decision faster and reducing the burden of depression for patients and healthcare systems. Cerba is again at the forefront of innovation for enlightening diagnosis, improving patient health management and facilitating the right prescription at the right time for the right patient."

Dekel Taliaz, CEO and Co-founder of Taliaz, said, "We are delighted to sign this landmark agreement with Cerba HealthCare to help advance our mental health technology. Their scientific culture and extensive network will expand market entry for PREDICTIX towards global outreach. By leveraging the power of big data and AI in easy-to-use and time saving clinician tools, we are committed to bringing safe and efficient solutions to accelerate recovery and reduce suffering of patients with mental illness worldwide."

About Cerba HealthCare Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier and optimize the effectiveness of personalized medicine.

Every day, on 5 continents, the Group’s 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health. Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

About Cerba

Laboratoire Cerba, at the origin of the Cerba HealthCare Group and world reference in specialized clinical pathology, performs complex analyses on behalf of other medical laboratories that cannot proceed with their own analyses due to the level of expertise, equipment and certification required.

For 50 years, Cerba’s medical and scientific teams have been assisting and advising healthcare professionals in the selection of the most relevant analyses and in the interpretation of the results to improve patient care. They are recognized by their peers in human genetics, onco-haematology, infectiology, endocrinology and immunology, pharmacotoxicology and metabolic diseases. With a panel of 1,300 exams covering 40 medical specialties, Cerba serves clinical pathology laboratories as well as private and public healthcare institutions in more than 50 countries.

For more information www.lab-cerba.com

About Taliaz

Taliaz is revolutionizing mental health treatment and management with PREDICTIX. Combining science with AI, PREDICTIX translates complex genetic, demographic and clinical patient data into a time-saving assessment, prescribing and management support tool for healthcare providers. PREDICTIX improves treatment prescribing accuracy and can save 12% in mental health costs. PREDICTIX is CE-registered and currently available for commercial use in the EU (in France, Belgium and Switzerland), United States, United Kingdom, Australia and Israel. Learn more at https://www.predictix.ai/.

]]>
10/21/2022 12:00:00 PM https://cerbalancetafrica.com.gh/news/press-releases/cerba-and-taliaz-to-leverage-artificial-intelligence/